Inoviv
Transforming Clinical Trials with Bespoke Solutions

The current high standards of medical care can largely be attributed to the clinical trials that objectively evaluates the safety and efficacy of any new drug or treatment. Clinical trials provide a scientific basis for advising and treating patients, which goes a long way in introducing new drugs and treatments. Besides, even when researchers do not obtain the desired outcomes, trial results can point scientists in the correct direction. To this end, the selection procedure of volunteers plays one of the most crucial roles in determining the success of clinical trials. Most of the drug or treatment approval fails due to inefficient patient enrollment into a trial, which results in significant revenue loss for pharmaceutical companies. Further, several clinical trials are also plagued by lengthy endpoints to demonstrate treatment efficacy due to suboptimal treatment monitoring.

This is where London-based Inoviv takes centre stage with a targeted proteomics-based novel technology platform to support pharmaceutical companies with biomarker test development. The company’s tailored biomarker tests identify patients and demonstrate treatment efficacy for novel therapies. It helps pharmaceutical companies in patient identification and stratification by optimising patient enrollment into a trial, which significantly improves the chances of superior outcomes. In addition, Inoviv’s platform also generates robust data to measure treatment efficacy on an ongoing basis throughout a clinical trial, increasing efficiency and success rate to a large extent.

The novel targeted proteomics of Inoviv uses mass spectrometry-based targeted proteomics and unique algorithms and workflows to detect biomarkers with impeccable specificity and throughput.

With mass spectrometry technique, the company’s targeted proteomics platform measures the mass-to-charge ratio of a wide range of molecules, delivering unrivalled specificity to distinguish different protein isoforms or modifications.Unlike other mass spectrometry-based platforms, Inoviv’s quadrupole systems allow targeted, high throughput and highly reproducible quantification that is ideally suited for clinical applications. Further, the triple quadrupole mass spectrometry systems also enable the development of multiplexed assays to quantify hundreds of analytes in a single assay.

Additionally, the platform can analyse 3000 biofluid/tissue samples per day and maintain robust analytical performance across different instruments, instrument vendors, and laboratories. Not only this, the unique algorithms and mass spectrometry workflows enables the platform to improve throughput compared to other targeted proteomics platforms and protein detection technologies. It allows high throughput testing of multiplexed protein, peptide, lipid, and metabolite biomarker panels.

More importantly, Inoviv’s biomarker tests are designed to simultaneously measure more than 50 fully calibrated biomarkers that allow the company to develop bespoke tests specific to disease subtypes, ideal for supporting targeted therapies. It helps to demonstrate drug efficacy across multiple aspects of disease pathology and identify patients who respond to drugs in healthcare settings.

Established in 2017, the company operates from CLIA-certified laboratories in the US and GLP/ GCP labs in the UK. The company boasts of a proficient team of experts across diverse fields, including the pharmaceutical industry, clinical practice and academia. The team collaborates with the clients to understand their needs and adapts biomarker tests to their specific needs, depending on the stage of development and the mechanism of action of their therapeutic.

With its path-breaking technology, Inoviv’s biomarker tests have supported several pharmaceutical companies in running successful clinical trials as well as maximising access to marketed therapies. The company now plans to add more innovative features on its platform to help its clients succeed in their clinical trials and enhance the speed-to-market of novel treatments and drugs.